English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/81930
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Title

Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer

AuthorsMartínez-Iglesias, Olaia ; Ruiz-Llorente, Lidia ; Sánchez-Martínez, Ruth; García, Laura; Zambrano, Alberto ; Aranda, Ana
Issue Date2008
PublisherSpringer
CitationClinical and Translational Oncology 10(7): 395-398 (2008)
AbstractHistone deacetylases (HDACs) remove the acetyl groups of lysine residues of histone tails leading to chromatin compaction and transcriptional repression. In addition, HDACs can also influence transcription-independent events such as mitosis or deoxyribonucleic acid (DNA) repair and deacetylate nonhistone proteins involved in cell proliferation and death, altering their function. Histone deacetylase inhibitors (HDACi) constitute a promising treatment for cancer therapy due to their low toxicity. HDACi have been shown to induce differentiation, cell-cycle arrest, and apoptosis and to inhibit migration, invasion, and angiogenesis in many cancer cell lines. In addition, these compounds inhibit tumor growth in animal models and show antitumor activity in patients. HDACi alone and in combination with a variety of anticancer drugs are being tested in clinical trials, showing significant anticancer activity both in hematological and solid tumors. SAHA (vorinostat, Zolinza) was the first HDACi approved by the US Food and Drug Administration to enter the clinical oncology market for treating cutaneous T-cell lymphoma (CTCL) and is being tested for other malignancies.
URIhttp://hdl.handle.net/10261/81930
DOI10.1007/s12094-008-0221-x
Identifiersdoi: 10.1007/s12094-008-0221-x
issn: 1699-048X
e-issn: 1699-3055
Appears in Collections:(IIBM) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.